Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 4 | -$0.84 | -$0.78 | -$0.82 |
Q2 2025 | 2 | -$0.83 | -$0.83 | -$0.83 |
Q3 2025 | 2 | -$0.71 | -$0.71 | -$0.71 |
Q4 2025 | 2 | -$0.75 | -$0.75 | -$0.75 |
Q1 2026 | 1 | -$0.78 | -$0.78 | -$0.78 |
Q2 2026 | 1 | -$0.78 | -$0.78 | -$0.78 |
Q3 2026 | 1 | -$0.77 | -$0.77 | -$0.77 |
Q4 2026 | 1 | -$0.76 | -$0.76 | -$0.76 |
Denali Therapeutics Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.63 earnings per share for the quarter, missing analysts' consensus estimates of $-0.6 by $0.03. The company had revenue of 0 for the quarter and had revenue of 330.53 M for the year. Denali Therapeutics Inc. has generated $-1 earnings per share over the last year ($-1.06 diluted earnings per share) and currently has a price-to-earnings ratio of -7.43. Denali Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | -$0.60 | -$0.63 | -0.03 | $6.30 M | $0 |
08/01/2024 | Q2 2024 | -$0.68 | -$0.59 | 0.09 | $10.00 M | $0 |
05/07/2024 | Q1 2024 | -$0.67 | -$0.68 | -0.01 | $0 | |
02/27/2024 | Q4 2023 | -$0.86 | $-305,043,000 | |||
11/07/2023 | Q3 2023 | -$0.83 | -$0.72 | 0.11 | $11.16 M | $1.27 M |
08/08/2023 | Q2 2023 | -$0.68 | $1.34 | 2.02 | $39.51 M | $294.12 M |
05/08/2023 | Q1 2023 | -$0.71 | -$0.80 | -0.09 | $35.14 M | |
02/27/2023 | Q4 2022 | -$0.78 | -$0.74 | 0.04 | $10.28 M | |
11/03/2022 | Q3 2022 | -$0.83 | -$0.84 | -0.01 | $17.02 M | $3.56 M |
08/08/2022 | Q2 2022 | -$0.52 | -$0.48 | 0.04 | $44.66 M | $52.48 M |
05/05/2022 | Q1 2022 | -$0.47 | -$0.52 | -0.05 | $42.14 M | |
02/28/2022 | Q4 2021 | -$0.41 | -$0.62 | -0.21 | $12.51 M | |
11/04/2021 | Q3 2021 | -$0.51 | -$0.69 | -0.18 | $30.28 M | $5.29 M |
08/04/2021 | Q2 2021 | -$0.37 | -$0.50 | -0.13 | $27.92 M | $22.94 M |
05/05/2021 | Q1 2021 | -$0.58 | $7.92 M | |||
02/26/2021 | Q4 2020 | $2.04 | $316.82 M | |||
11/05/2020 | Q3 2020 | $3.57 | -$0.54 | -4.11 | $494.27 M | $9.39 M |
08/07/2020 | Q2 2020 | -$0.61 | -$0.56 | 0.05 | $3.67 M | $5.85 M |
05/07/2020 | Q1 2020 | -$0.57 | -$0.55 | 0.02 | $3.60 M | |
02/27/2020 | Q4 2019 | -$0.53 | -$0.57 | -0.04 | $4.67 M |
Denali Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
The conference call for Denali Therapeutics Inc.'s latest earnings report can be listened to online.
The conference call transcript for Denali Therapeutics Inc.'s latest earnings report can be read online.
Denali Therapeutics Inc. (:DNLI) has a recorded annual revenue of $330.53 M.
Denali Therapeutics Inc. (:DNLI) has a recorded net income of $330.53 M. Denali Therapeutics Inc. has generated $-1.06 earnings per share over the last four quarters.
Denali Therapeutics Inc. (:DNLI) has a price-to-earnings ratio of -7.43 and price/earnings-to-growth ratio is -2.35.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED